CG Oncology, Inc. Common stock (CGON) NASDAQ
53.72
-2.37(-4.23%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
53.72
-2.37(-4.23%)
Currency In USD
| Previous Close | 56.09 |
| Open | 55.85 |
| Day High | 56.78 |
| Day Low | 53.52 |
| 52-Week High | 75.5 |
| 52-Week Low | 23.65 |
| Volume | 939,814 |
| Average Volume | 1.23M |
| Market Cap | 4.74B |
| PE | -22.96 |
| EPS | -2.34 |
| Moving Average 50 Days | 66.42 |
| Moving Average 200 Days | 50.15 |
| Change | -2.37 |
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
GlobeNewswire Inc.
Feb 27, 2026 1:30 PM GMT
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) N
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the TD Cowen 46th Annua
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
GlobeNewswire Inc.
Jan 09, 2026 1:30 PM GMT
- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an investigational therapy in intermedia